PSGL-1 can also be a therapeutic target; immunotherapy with anti-PSGL-1 mAbs was used in combination with mCRP blockage-induced, complement-mediated lysis of multiple myeloma cells in vivo (111). The gene discussed is SELPLG; the disease is AL amyloidosis.